Replies to post #13051 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

Sorry... let me rephrase.

The "invention" descibed in LRG's post suggests altering the fucose in the glycolised end of the ADCC MAb would enhance its activity in ADCC. Could you suggest a mechanism of how this enhancement might work.